Pediatric OCD Dosing Against the SSRI Black-Box Warning
Both teenagers carry the identical FDA black-box warning on the identical drug class — but the OCD patient's own diagnosis requires reaching a meaningfully higher dose to get there, sharpening a risk conversation the depression patient's case leaves comparatively familiar.
C.H., a 16-year-old girl, is a sophomore and a competitive swimmer who has been missing practice for the past two months, which her coach flagged to her parents as unusual. She lives with both parents and a younger brother, and has no significant medical history.
She was diagnosed with major depressive disorder ten weeks ago after her school counselor noted persistent low mood, loss of interest in swimming, and sleep disruption lasting over a month, without any prior depressive episode. Her PHQ-9 at diagnosis was 18, moderately severe. Fluoxetine was started at 10 mg, titrated to 20 mg over four weeks — a standard, guideline-typical depression dose for her age — and she has now been at that dose for six weeks with a PHQ-9 of 11, a meaningful improvement.
Every adolescent started on an SSRI carries the FDA's black-box warning for increased suicidal ideation risk in patients under 25, requiring closer monitoring — typically weekly visits for the first month, then biweekly through twelve weeks. Her case represents that monitoring requirement in its most familiar form: a standard depression dose, reached through a standard titration, with a response that is already tracking in the expected direction, and no report of new or worsening suicidal thinking at any of her scheduled visits so far. The follow-up visit in front of the group today is a routine check-in on a plan that is, so far, working as intended — the version of this conversation most clinicians have had many times before, and the baseline against which the next patient's meaningfully longer climb is worth measuring.
A monitoring plan already working as expected
Her trajectory is what we hope to see: standard dose, expected titration schedule, measurable improvement, and no suicidality signal at any of her monitoring visits so far. This is the black-box warning doing exactly the job it was designed for — close early observation on a drug that helps most adolescents who take it, with a real but small subset at elevated risk the monitoring schedule is built to catch.
Agreed, and worth stating plainly for the record precisely because her case is the calm one: this is what makes the next patient's situation a genuinely different risk conversation rather than more of the same. Her visits have already spaced to biweekly per the standard schedule, which was appropriate — she moved past the highest-risk early window weeks ago with no concerning signal at any check-in.
I'll keep her family engaged in the monitoring plan through week twelve as scheduled, and continue the swim-return conversation with her coach directly if it would help pace her back without pressure. Nothing here needs escalation — just the plan as written.
Agreed: fluoxetine continued unchanged at 20 mg, monitoring visits continuing on the standard biweekly schedule through week twelve, and swim-team return continued at her current gradual pace.
No disagreement recorded for Case A — the group's discussion here was largely about establishing the familiar baseline that the next patient's case departs from.
R.A., a 14-year-old boy, plays trumpet in his middle school's honor band and has an older sister with a history of anxiety that their parents mention readily when asked about family history. He has no significant medical history of his own.
He was diagnosed with OCD four months ago after his band director noticed him repeatedly re-checking that his trumpet's valves were properly seated before every rehearsal, sometimes for ten minutes at a time, alongside contamination concerns about shared mouthpieces that had already led him to avoid a school trip. Fluoxetine was started at 10 mg, the same starting dose as C.H.'s, but his diagnosis requires a meaningfully higher target — fluoxetine's labeled pediatric OCD range runs to 60 mg/day, roughly triple the 20 mg standard depression dose for his age, well above where C.H.'s trial stopped. The 80 mg ceiling often quoted for OCD is the adult figure; it is not the labeled pediatric one, and reaching for it here would put him above the range studied in children. He is currently at 40 mg after eight weeks of titration, with a Y-BOCS of 24, down modestly from 27 at diagnosis.
The same FDA black-box warning that governed C.H.'s monitoring plan applies to him identically — but the higher target dose his OCD diagnosis requires means more titration steps, each one a fresh dose increase during the specific early window the warning is most concerned about, and a longer total run before the trial can even be judged complete, since OCD's own adequate-trial window runs to twelve weeks at the target dose rather than from treatment start. His family history of anxiety in his sister doesn't change the black-box calculus directly, but it is the kind of detail that makes the group want to ask about his own mood and any suicidal thinking with real specificity at each visit, not assume the absence of a spontaneous report means the absence of a symptom worth naming.
Monitoring a longer, higher climb
He's not near his target dose yet, which means we're not past the highest-risk early window the way C.H. is — each further increase toward 60 mg is a fresh entry into that window, not a continuation of a plan already proven safe for him. I want weekly visits maintained until he reaches and holds his target dose, not stepped down to biweekly on the standard schedule the way hers just was.
I'd add that "no spontaneous report" isn't the same reassurance in a 14-year-old that it is in an adult, and his sister's anxiety history is a real, if nonspecific, reason to ask more directly rather than less. I'm not proposing anything different about the dose target itself — OCD genuinely needs it — only that the monitoring conversation at each visit should include a specific, structured suicidality question, not rely on him volunteering something a 14-year-old may not have the language or willingness to bring up unprompted.
I'll build that structured question into every visit through the full climb to target dose, and keep his parents explicitly looped in on what "weekly until stable at target" actually means for their schedule — this is a longer, more demanding monitoring commitment than a depression trial asks of a family, and they should understand why before they're several weeks into it wondering when it ends.
Agreed: continued titration toward the 60 mg target, weekly visits maintained (not stepped down) until he reaches and holds that target, and a structured, specifically-worded suicidality question added to every visit rather than relying on spontaneous report.
Not fully resolved: how many further dose-increase visits should trigger an explicit re-discussion with his parents about the cumulative monitoring burden versus how much further titration genuinely remains. The pediatric psychiatrist wanted that conversation deferred until he's closer to target; the clinical pharmacologist felt naming the full expected timeline now, rather than one step at a time, respected the family's ability to plan for it honestly.